Rotella Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Rotella Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-33,952	Closed	-$83K	–	65
2015 Q4	$83K	Sell	33,952 -400	-1%	-$1.15K	0.07%	333
2015 Q3	$103K	Buy	34,352 +13,500	+65%	+$58.3K	0.03%	421
2015 Q2	$86K	Buy	20,852 +4,000	+24%	+$15.9K	0.07%	298
2015 Q1	$73K	Buy	+16,852	New	+$60.7K	0.06%	420
2014 Q4	–	Sell	-22,852	Closed	-$76K	–	369
2014 Q3	$76K	Buy	22,852 +9,052	+66%	+$23.7K	0.08%	199
2014 Q2	$35K	Buy	13,800 +1,500	+12%	+$3.2K	0.03%	333
2014 Q1	$28K	Buy	+12,300	New	+$25.7K	0.03%	218

Other funds holding CPRX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rotella Capital Management's CPRX Position: Q1 2016 in Review

Rotella Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2016, closing a stake of 33,952 shares — an estimated $83K sold.

Rotella Capital Management first reported a position in CPRX in Q1 2014 and held it in 7 quarters. The position peaked at $103K in Q3 2015. 73 funds tracked by Wall St. Rank hold CPRX as of Q1 2016.

Rotella Capital Management reported no remaining Catalyst Pharmaceutical position as of Q1 2016 after selling out during the quarter.
Rotella Capital Management sold 33,952 Catalyst Pharmaceutical shares in Q1 2016, an estimated $83K.
Rotella Capital Management first reported a position in Catalyst Pharmaceutical in Q1 2014 and held it in 7 quarters.
Rotella Capital Management's Catalyst Pharmaceutical position peaked at $103K in Q3 2015.
73 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2016.

Based on Rotella Capital Management's 13F filing for Q1 2016, filed 13 May 2016.